Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol MMP2 contributors: mct - updated : 05-02-2015
HGNC name matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
HGNC id 7166
ASSOCIATED DISORDERS
corresponding disease(s) NAO , WINCH1
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
constitutional     --over  
in inflammatory bowel diseases, poly and dermatomyositis
tumoral     --over  
in prostate tumor and in malignant mesothelioma and in thymoma with poor prognosis
tumoral       gain of function
in head and neck cancer (by CSF2) and in invasive glioma (inhibited by PTEN)
tumoral     --over  
in head and neck carcinoma with lymph node metastasis and in breast carcinoma with short survival
constitutional       loss of function
linked with an autosomal recessive form of multicentric osteolysis
constitutional     --low  
contribute to the endothelial dysfunction that is central to the pathophysiology of preeclampsia
constitutional     --over  
in scarred keratoconic cornea
tumoral       gain of function
in high expression of estrogen receptors associated with increased BCL2 levels in breast carcinoma
constitutional     --over  
have been detected after skin injury (jansen 2007)
constitutional     --over  
in women with pelvic organ prolapse (Connell 2008)
tumoral       gain of function
resulting from decreased ID4 expression in glioblastoma multiforme (GBM), may contribute to the morbidity and mortality of GBM patients
constitutional       gain of function
SPARC, MMP2 and MM9 were significantly up-regulated in intracranial aneurysms relative to the expression levels in the normal Circle of Willis arteries
Susceptibility
  • to toxic epidermal necrolysis and to Stevens-Johnson syndrome
  • to nasopharyngeal carcinoma
  • to intrauterine growth retardation (IUGR)
  • Variant & Polymorphism other
  • polymorphisms increasing the risk of nasopharyngeal carcinoma
  • MMP2 C-1306T mutation rate was higher within the IUGR (Gremlich 2007)
  • Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancer  
    ARP101 known as a selective matrix metalloproteinase-2 (MMP-2) inhibitor, strongly induced autophagy and autophagy-mediated cell death of cancer cells
    ANIMAL & CELL MODELS
  • a MONA-like progressive osteolysis and arthritis phenotype has been demonstrated in Mmp2-knockout mice